ProCE Banner Activity

PEARL: Palbociclib + Endocrine Therapy vs Capecitabine in Postmenopausal Women With HR+/HER- MBC and Previous AI Therapy

Slideset Download
Conference Coverage
No significant differences in PFS benefit between palbociclib plus endocrine therapy and single-agent capecitabine, including in women with visceral disease, ESR1 wildtype tumors, and luminal breast cancer, but combination better tolerated.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen